2024 |
Novartis AG - ADR
|
Independent Director |
360 K |
0.0 % |
2024 |
Charles River Laboratories International Inc.
|
Independent Director |
340.5 K |
0.2 % |
2024 |
Maze Therapeutics Inc.
|
Independent Director |
113.4 K |
- |
2023 |
Novartis AG - ADR
|
Independent Director |
360 K |
0.0 % |
2023 |
Charles River Laboratories International Inc.
|
Independent Director |
339.8 K |
0.7 % |
2022 |
Novartis AG - ADR
|
Independent Director |
360 K |
0.0 % |
2022 |
Charles River Laboratories International Inc.
|
Independent Director |
337.4 K |
11.3 % |
2021 |
Novartis AG - ADR
|
Independent Director |
360 K |
- |
2021 |
Charles River Laboratories International Inc.
|
Independent Director |
303.1 K |
-10.6 % |
2020 |
Charles River Laboratories International Inc.
|
Independent Director |
339.1 K |
- |
2020 |
Novartis AG - ADR
|
Independent Director |
- |
- |
2019 |
Novartis AG - ADR
|
Independent Director |
360 K |
0.0 % |
2019 |
Charles River Laboratories International Inc.
|
Independent Director |
- |
- |
2018 |
Novartis AG - ADR
|
Independent Director |
360 K |
0.0 % |
2017 |
Novartis AG - ADR
|
Independent Director |
360 K |
1.4 % |
2016 |
Novartis AG - ADR
|
Independent Director |
355 K |
29.1 % |
2015 |
Novartis AG - ADR
|
Independent Director |
275 K |
- |